The shares are up $1.54 to $19.36 in afternoon trading with Elevidys remaining on the market in the U.S.
Claim 30% Off TipRanks
New trading tool for SRPT bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- FDA approves new safety warning and revised indication for Sarepta’s Elevidys
- FDA appoints Richard Pazdur as Director of CDER
- Wave Life Sciences price target lowered to $16 from $18 at Wells Fargo
- Sarepta price target lowered to $20 from $22 at Barclays
- Sarepta upgraded to Outperform from Neutral at Mizuho